

---

STATUTORY INSTRUMENTS

---

**2019 No. 775**

**The Human Medicines (Amendment  
etc.) (EU Exit) Regulations 2019**

**PART 12**

Amendment of Part 12 (dealings with medicinal products)

**[<sup>F1</sup>Amendment of regulation 255B (exception to Article 25 of Commission Regulation 2016/161: health care institutions)**

**196A.** In regulation 255B, after “medicinal products to the public” in the first place it occurs insert “in Northern Ireland”.]

---

**Textual Amendments**

- F1** Regs. 196, 196A substituted for reg. 196 (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, [Sch. 2 para. 150](#)

---

**Commencement Information**

- I1** Reg. 196A in force at 31.12.2020 on IP completion day (in accordance with [2020 c. 1, Sch. 5 para. 1\(1\)](#)), see [reg. 1](#)

**Changes to legislation:**

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 196A.